Skip to main content
SpringerLink
Log in

Morphine Oral - Elan Corporation

Avinza™

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Notes

  1. This profile has been selected from R&D Insight™, a pharmaceutical intelligence database produced by Adis International Ltd.

Reference

  1. Ligand Pharmaceuticals. FDA approves AVINZA once-daily for chronic,moderate-to-severe pain; Ligand planning second quarter launch into $2.3 billion market. Media Release: [3 pages], 21 Mar 2002. Available from URL: http://www.ligand.co

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Morphine Oral - Elan Corporation. Drugs R&D 3, 208–209 (2002). https://doi.org/10.2165/00126839-200203030-00015

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200203030-00015

Keywords

Search

Navigation